Nat Methods：新方法有助于大规模检测癌症的生物标记物

癌症蛋白质组专家Amanda Paulovich博士领导的国际研究团队开发了大规模标准化进行蛋白检查的方法，该方法有助于鉴定疾病相关生物标记物和药物开发。相关报道发表在近期的Nature Methods杂志上。

Paulovich博士开发的新技术能够系统，准确的分析人类蛋白质组。科学家能够同时准确的检测来自不同样本的数百个蛋白的表达量。来自西雅图，波士顿和韩国的科学家采用该方法分别检测了人类乳腺癌细胞的319个蛋白的表达情况，表明该方法是在全球各地都能通用。

Paulovich博士称，该技术是在蛋白质检测领域是革命性的。该技术无疑能够加快临床前试验的进度。
Paulovich博士采用高敏感性，靶向蛋白检测技术，称之为多重反应检测质谱仪（multiple reaction monitoring mass spectrometry,  MRM-MS）。采用该技术每台仪器能够每天检测20个临床样本，具有高通量的特点。

Paulovich博士希望该技术能够在全世界的实验室应用。为此她已经在开发开源网站来储存高通量的研究资源，该门户网站有望在2014年初问世。(转化医学网360zhyx.com)


原文链接：

---

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins

Multiple reaction monitoring (MRM) mass spectrometry has been successfully applied to monitor targeted proteins in biological specimens, raising the possibility that assays could be configured to measure all human proteins. We report the results of a pilot study designed to test the feasibility of a large-scale, international effort for MRM assay generation. We have configured, validated across three laboratories and made publicly available as a resource to the community 645 novel MRM assays representing 319 proteins expressed in human breast cancer. Assays were multiplexed in groups of >150 peptides and deployed to quantify endogenous analytes in a panel of breast cancer–related cell lines. The median assay precision was 5.4%, with high interlaboratory correlation (R2 > 0.96). Peptide measurements in breast cancer cell lines were able to discriminate among molecular subtypes and identify genome-driven changes in the cancer proteome. These results establish the feasibility of a large-scale effort to develop an MRM assay resource.

来源：bioon